GlassScriptPhysician profile
Swati Chalavarya
NPI 1699030734
$6,911.62
in general payments reported to CMS, 2019-2025
42 companies · $1,786 in 2025
The $1,786 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.02 · 2020: $1,055 · 2021: $760 · 2022: $72.63 · 2023: $873 · 2024: $2,325 · 2025: $1,786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,698 · Travel and Lodging: $258 · Education: $27.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,697.81 |
| Travel and Lodging | $257.63 |
| Education | $27.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,047.06 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Medtronic, INC. | $856.24 | 2023-2025 | Minimed 780g |
| Amgen INC. | $646.35 | 2021-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $559.13 | 2020-2025 | Mounjaro, Zepbound, Humulin |
| Sanofi-Aventis U.S. LLC | $437.90 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $249.39 | 2020-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $249.10 | 2023-2025 | |
| Abbvie INC. | $247.95 | 2020-2025 | Synthroid |
| Dexcom, INC. | $220.58 | 2019-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $204.00 | 2019-2025 | Korlym |
| Radius Health, INC. | $164.18 | 2020-2025 | Tymlos |
| Ibsa Pharma INC. | $149.57 | 2020-2024 | Tirosint, Licart, Tirosint |
| Xeris Pharmaceuticals, INC. | $148.32 | 2020-2024 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $140.59 | 2020 | |
| Mannkind Corporation | $132.14 | 2020-2021 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $128.39 | 2021-2025 | Omnipod |
| Astellas Pharma US INC | $111.27 | 2024-2025 | Veozah |
| Tandem Diabetes Care, INC. | $110.88 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Recordati_rare_diseases_inc. | $109.35 | 2024-2025 | Isturisa, Signifor Lar |
| Neurocrine Biosciences, INC. | $104.16 | 2025 | |
| Antares Pharma, INC. | $94.47 | 2020-2025 | Xyosted |
| Beta Bionics, INC. | $93.35 | 2024 | Ilet Bionic Pancreas |
| Merck Sharp & Dohme LLC | $73.54 | 2020-2021 | |
| Zealand Pharma US, INC. | $69.54 | 2020 | |
| Abbott Laboratories | $63.13 | 2023-2025 | Freestyle Libre 2 |
| Kyowa Kirin, INC. | $62.69 | 2024 | Crysvita |
| Amarin Pharma, INC. | $59.37 | 2020 | |
| Ascendis Pharma Endocrinology INC | $53.48 | 2025 | Yorvipath |
| Amneal Pharmaceuticals LLC | $41.39 | 2023-2024 | Unithroid |
| Halozyme INC | $38.79 | 2023 | |
| Nevro Corp. | $31.09 | 2023-2024 | Senza |
| Globus Medical, INC. | $26.66 | 2025 | Senza |
| Horizon Therapeutics Plc | $24.84 | 2023 | Tepezza |
| Medtronic Minimed, INC. | $23.80 | 2020 | |
| Averitas Pharma INC. | $22.46 | 2025 | Qutenza |
| Madrigal Pharmaceuticals | $21.63 | 2025 | Rezdiffra |
| Soleno Therapeutics, INC. | $19.37 | 2025 | Vykat Xr |
| Daiichi Sankyo INC. | $18.44 | 2020 | |
| Glaxosmithkline, LLC. | $14.87 | 2025 | Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $14.71 | 2020 | |
| Novartis Pharmaceuticals Corporation | $14.42 | 2024 | |
| Grt US Holding, INC. | $13.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Swati Chalavarya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.